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Galectin-3: a potential biomarker  
for diagnostics of heart failure
AbstrAct
Heart failure is a dysfunction with varied etiology; one of possible causes is anticancer treatment 
with anthracyclines. Rapid diagnosis is impor tant because the disease is associated with high 
mor tality and morbidity. The only biomarkers fully approved for diagnostics of hear t failure 
are natriuretic peptides. They are secreted by ventricular muscle cells in response to volume 
and pressure overload. However, their concentration can be influenced by other factors, such 
as age or gender. A potential marker, not affected by these issues might be galectin-3. Current 
studies showed that galectin can play par ticularly significant role in myocardial fibrosis and 
inflammation. Elevated galectin-3 concentration has been observed in such cardiovascular 
diseases as hear t failure,  atherosclerosis, stroke and myocardial infarction. The review sum-
marizes results of studies which indicate the role of galectin-3 in inducing fibrosis and cardiac 
remodelling (processes which influence disease progression and prognosis) and showed its 
potential diagnostic value.
(Forum Zaburzeń Metabolicznych 2018, tom 9, nr 3, 126–131)
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Galectins are family of proteins with 
characteristic carbohydrate recognition 
domain (CRD), consisting of 130 amino 
acids. CRD is responsible for recogniz-
ing b-galactosides, especially glycans 
with N-acetylgalactosamine. 15 proteins 
from this family has been discovered so 
far. They were divided, according to their 
structure, to [1]:
1. Prototypical galectins: one CRD do-
main; two subunits may form dimer; 
galectins with this structure are: Gal-1, 
-2, -5, -7, -10, -11, -13, -14, -15.
2. Tandem galectins: two CRD domains 
joined by a sequence of 70 amino acids; 
galectins with this structure are: Gal-4, 
-6, -8, -9, -12.
3. Chimeric galectins: single CRD fused 
to N-terminal sequence of 120 amino 
acids; they can form pentamers; Gal-3 
is the only member of this group.
Galectins can be found in many different 
cells (skeletal muscles, neurons, kidneys, 
placenta, active macrophages, mastocytes, 
epithelial cells of gastrointestinal tract, 
respiratory system). Their location and in-
tracellular function depends on type and 
condition of cells [1]. Galectin-3 (Gal-3) 
expression was observed in neutrophils, 
macrophages, fibroblasts, mast cells, os-
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teoclasts, cancer cells. Typical tissues for 
galectin-3 presence include lungs, spleen, 
stomach, colon, adrenal glands, uterus, 
ovaries. In lesser amounts, galectin-3 can 
be found in heart, kidneys, brain, pancreas, 
liver [2]. Current studies showed that ga-
lectin can play particularly significant role 
in myocardial fibrosis and inflammation. It 
was also found, that galectin can contrib-
ute to tumour growth, angiogenesis, and 
metastatic progression. Elevated galectin-3 
concentration has been observed in such 
cardiovascular diseases as heart failure, 
atherosclerosis, stroke and myocardial in-
farction [3–5].
Heart failure is a dysfunction with varied 
etiology; one of possible causes is antican-
cer treatment with anthracyclines. Rapid 
diagnosis is important because the disease is 
associated with high mortality and morbid-
ity. The only biomarkers fully approved for 
diagnostics of heart failure are natriuretic 
peptides (especially BNP and NT-proBNP) 
which are secreted by ventricular muscle 
cells in response to volume and pressure 
overload. However, their concentration 
can be influenced by other factors, such as 
age, gender, renal function, anaemia, over-
weight, atrial fibrillation, and volume status 
showing that it reflects haemodynamic con-
dition rather than structural abnormalities 
of the heart [6, 7]. A potential marker, not 
affected by these issues might be galectin.
Of all galectins, galectin-3 is particularly in-
teresting as it has effect on cardiac fibrosis 
and remodelling: both mechanisms influ-
encing the development and progression 
of heart failure [7]. Animal studies con-
firmed upregulation of Gal-3 expression 
in myocardial biopsies of rats with cardiac 
hypertrophy [8]. Myocardial level of Gal-
3 is nearly undetectable in myocytes while 
increasing significantly in fibroblasts [9]. 
A very important feature of Gal-3 is its in-
fluence on fibrosis, fibroblasts proliferation 
and synthesis of type 1 collagen which forms 
rigid protein fibers resistant to stretching 
[2]. It was found out in animal studies that 
pathologic mechanism of collagen accumu-
lation and myocardial remodelling is asso-
ciated with rapid increase in Gal-3 concen-
tration [9]. Analysis of rats cardiovascular 
biopsies revealed that severe heart fibro-
sis and clinical diagnosis of heart failure 
is preceded by increased Gal-3 level [10]. 
These results indicated the role of Gal-3 in 
inducing fibrosis and cardiac remodelling 
(processes which influence disease progres-
sion and prognosis) and showed its poten-
tial diagnostic value.
It was observed in PRIDE and COACH 
clinical studies that Gal-3 was a prognostic 
marker for 60-day and 18-month mortality 
and rehospitalization of patients with acute 
heart failure [11, 12]. Long-term (up to 
4 years) predictive value of Gal-3 was found 
by Shah et al. in the group of patients with 
acutely decompensated heart failure; predic-
tion was independent of echocardiographic 
markers of disease severity [8]. Similar find-
ings, concerning association of increased 
Gal-3 level with increased probability of 
death or rehospitalization, were described 
in patients with chronic heart failure [13–16].
Gal-3 prognostic value was negated in 
some studies corrected with renal function 
parameters and natriuretic peptide lev-
el. Therefore, despite the results of huge 
metanalysis (> 8,000 patients with acute 
or chronic heart failure) confirming the as-
sociation between Gal-3 and increased risk 
of all-cause mortality and cardiovascular 
mortality, the role of Gal-3 measurement 
in patients with renal dysfunction remained 
a subject of doubt [17]. Predictive value of 
Gal-3 in the assessment of heart failure risk 
was evaluated in 2-year study on 100 pa-
tients with acute coronary syndrome. The 
study confirmed the association between 
increased Gal-3 level and development of 
heart failure. In patients, whose initial Gal-
3 concentration was higher than median 
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value the risk of heart failure was two times 
higher compared to the control group. Also, 
a poor but statistically significant negative 
correlation between Gal-3 and LVEF (left 
ventricular ejection fraction) was observed. 
The authors of the study applied for justi-
fying the use of Gal-3 as marker of heart 
remodelling leading to heart failure [18]. 
The results of the study on general popu-
lation, in a group of nearly 8,000 patients, 
with average observation period of 10 years, 
provided evidence that Gal-3 correlated 
with multiple cardiovascular risk factors, 
including lipid levels, diabetes mellitus, 
blood pressure, BMI, kidney function and 
NT-proBNP level. There was a strong associ-
ation between Gal-3 levels and age and a par-
ticularly strong correlation between Gal-3 
levels and the risk of cardiovascular disease 
in women. It was shown that in general pop-
ulation the marker concentration correlated 
with the risk of death and was a predictor 
of all-cause mortality [12].Another study 
on 4000 patients with similar follow up also 
confirmed that elevated Gal-3 level was an 
independent predictor of cardiac failure and 
death from any cause, even after correction of 
renal function and BNP measurements [19]. 
In the elderly population with unknown car-
diovascular diseases, elevated Gal-3 level 
was associated with an increased risk of car-
diovascular death in the 11-year period [20].
A study on 120 patients with hypertension 
with or without clinically apparent heart 
failure has recently been carried out on 
Polish population. There was no significant 
difference in initial Gal-3 concentration be-
tween heart failure and non-heart failure 
patients. Although increased Gal-3 concen-
tration was not shown to influence the risk 
of apparent heart failure in patients with 
hypertension, the authors stated that ad-
dition of Gal-3 measurement to NT-proB-
NP assessment provided better diagnosis 
of heart failure [21].Potential prognostic 
value of galectin was recently observed by 
Imran et al. and Miro et al. [22, 23], they 
found that galectin level was associated 
with all-cause mortality, cardiovascular 
mortality and heart failure.
Based on the results of clinical trials, rec-
ommendations for use of Gal-3 in routine 
clinical practice have been formulated. 
According to the ACC/AHA (American 
College of Cardiology/American Heart As-
sociation) guidelines, monitoring of Gal-3 
level is recommended in acute and chronic 
heart failure, to predict hospitalization or 
death risk, and as an addition to natriuretic 
peptides for risk stratification and disease 
progression [24]. Different opinion was 
presented by the ESC (European Society 
of Cardiology) experts who, according to 
the studies’ findings, did not allow Gal-3 to 
be included in routine clinical practice [6].
The role of Gal-3 in apoptosis and cell cycle 
regulation is widely known [9]. Gal-3 levels 
are considered to be associated with the po-
tential for tumour progression and spread, 
inhibition of breast cancer cell apoptosis, 
and resistance to treatment [25–27]. Avail-
able data indicate Gal-3 as a potential pre-
dictor of oncological mortality [9]. It seems 
that measurement of this marker may be 
important in the diagnosis of breast cancer, 
due to the relatively high level of Gal-3 
expression in triple negative breast cancer 
[26, 27]. The results of studies in patients 
with breast cancer did not confirm that 
monitoring of Gal-3 levels was relevant 
for risk assessment or early diagnosis of 
anthracycline-induced cardiotoxicity. In 
the group of nearly 80 patients treated with 
doxorubicin and trastuzumab, no statisti-
cally significant changes were observed in 
Gal-3 levels within 3 months after starting 
treatment while troponin I and myeloper-
oxidase have been found to be useful in 
the early diagnosis of cardiotoxicity [28]. 
Quarterly monitoring of changes in Gal-3 
level over a longer 15-month time period 
did not change this result. In a group of 
vv In the elderly 
population with unknown 
cardiovascular diseases, 
elevated Gal-3 level 
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anincreased risk of 
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Table 1. Pros and cons for routine Gal-3 measurements in cardio-oncological patients
Pros Cons
They are considered adequate in routine clinical  
practice in United States in patients with acute and 
chronic heart failure (American College of Cardiology/ 
/American Heart Association)
They are considered inadequate in routine 
clinical practice in Europe in patients with 
acute and chronic heart failure (European 
Society of Cardiology)
They are useful for assessment of severity of heart 
failure, the risk of death, re-hospitalization and better 
planning for the care of a diagnosed patient
Gal-3 is not a specific cardiac marker
Routine diagnosis of cardiac patients is supported by 
outcomes of clinical trials 
Elevated level of Gal-3 may be associated 
with renal dysfunction accompanying the 
heart failure
Gal-3 plays a particularly significant role in myocardial 
fibrosis and inflammation; it is nearly undetectable in 
myocytes while increasing significantly in fibroblasts
Data available for the oncologic population 
is insufficient as Gal-3 can also contribute to 
tumour growth, angiogenesis, and metastatic 
progression
Gal-3 plays a role in other cardiovascular diseases as 
atherosclerosis, stroke and myocardial infarction
Results of studies in patients with breast 
cancer did not confirm that monitoring of 
Gal-3 levels was relevant for risk assessment 
or early diagnosis of anthracycline-induced 
cardiotoxicity
It is a potential heart failure marker, not affected by 
age, gender, anaemia, overweight, atrial fibrillation,  
and volume status
Gal-3 concentration was not shown to in-
fluence the risk of apparent heart failure in 
patients with hypertension
It correlates with multiple cardiovascular risk factors, 
including lipid levels, diabetes mellitus, blood pres-
sure, BMI, kidney function and NT-proBNP level
There is a negative correlation between Gal-3 and 
LVEF
78 patients treated with doxorubicin and 
trastuzumab, no increase in Gal-3 was seen 
in three-month intervals. Similarly to the 
authors of the earlier study, the greatest 
chance for early diagnosis of cardiotoxic-
ity was seen in the monitoring of changes 
in the level of myeloperoxidase [29]. The 
results of another analysis of 55 patients 
with breast cancer, one year after doxo-
rubicin, docetaxel and cyclophosphamide 
treatment showed elevated levels of Gal-
3 in only a small proportion of patients. 
Additionally, no statistically significant 
correlation with LVEF was found. It was 
considered that Gal-3 was not useful in the 
early diagnosis of cardiotoxicity, and fur-
ther research should focus on NT-proBNP 
[30]. Summary of pros and cons for routine 
Gal-3 measurements in cardio-oncological 
patients is presented in Table 1.
 US and European experts disagree on the 
introduction of routine Gal-3 measure-
ments in patients with heart failure to clin-
ical practice. The results of many studies 
indicated that Gal-3 may be a useful new 
tool for assessing the severity of the disease, 
the risk of death and re-hospitalization, and 
thus better planning for the care of a di-
agnosed patient [31, 32]. There is a great 
interest in the use of Gal-3 measurement 
in patients with heart failure and preserved 
ejection fraction [17]. Doubts are raised, 
among other things, by the fact that Gal-3 
is not a specific cardiac marker, and some 
studies suggested that its elevated level was 
associated with renal dysfunction accompa-
nying the heart failure [9]. Gal-3 profibrot-
ic properties have been observed in liver, 
blood and kidney fibrosis and in the dif-
ferentiation of myofibroblasts [9, 31]. The 
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potential for Gal-3 for routine diagnosis of 
cardiac patients is supported by a number of 
clinical trials, but there is still insufficient 
data available for the oncologic population, 
hence the need for further studies and the 
unambiguous determination of the useful-
ness of Gal-3 in these patients.
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